A nebulizer is a medical device that turns liquid medicine into mist or aerosol that you inhale directly into your lungs. Medications used to treat respiratory conditions such as asthma, cystic ...
Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...
Q3 2025 Management View Jonathan Solomon, CEO, stated that the third quarter of 2025 was an important period for BiomX, ...
MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical ...
“We are actively engaged with the FDA to promptly address their queries regarding the third-party nebulizer,” said Jonathan Solomon, Chief Executive Officer of BiomX. “Importantly, the FDA’s ...
Yupelri (revefenacin) is a prescription nebulizer used to treat chronic obstructive pulmonary disease (COPD). Yupelri’s cost may depend on factors such as your dosage, whether you have health ...
The U.S. Food and Drug Administration placed a clinical hold on a study of BiomX's cystic fibrosis treatment in order to review data on the third-party nebulizer used to deliver the drug. Patient ...
NESS ZIONA, Israel - BiomX Inc. (NYSE American:PHGE), a micro-cap biotechnology company currently valued at $15.69 million with shares trading at $0.59, reported Friday that it has addressed FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback